Press "esc" to clear
Go to Advanced Search

Showing results

110 of 1188

Article ID: 698802

MD Anderson and Accelerator Life Science Partners Launch Magnolia Neurosciences to Speed Development of Neuroprotective Therapies

University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, today announced the launch of Magnolia Neurosciences Corporation, a company developing a new class of neuroprotective medicines, with $31 million in Series A funding. The company will develop novel therapeutics based on discoveries made by researchers in MD Anderson’s Therapeutics Discovery division, including the Institute for Applied Cancer Science (IACS) and the Neurodegeneration Consortium (NDC).

Released:
13-Aug-2018 6:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    6-Aug-2018 4:15 PM EDT

Article ID: 698588

MD Anderson and Jazz Pharmaceuticals collaborate to evaluate potential treatment options for hematologic malignancies

University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.

Released:
6-Aug-2018 9:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
  • Embargo expired:
    6-Aug-2018 10:00 AM EDT

Article ID: 698586

Comprehensive CAR T-cell therapy pediatric guidelines developed by MD Anderson in collaboration with the Pediatric Acute Lung Injury and Sepsis Investigators network

University of Texas M. D. Anderson Cancer Center

Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology.

Released:
6-Aug-2018 8:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
suggestion1.png
  • Embargo expired:
    1-Aug-2018 2:00 PM EDT

Article ID: 698369

Microscopic Imaging Pierces the “Black Box” of Cancer Bone Metastasis

University of Texas M. D. Anderson Cancer Center

Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.

Released:
1-Aug-2018 9:40 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
samir_hanash.jpg
  • Embargo expired:
    12-Jul-2018 11:00 AM EDT

Article ID: 697285

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers

University of Texas M. D. Anderson Cancer Center

A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment to improve eligibility criteria for lung cancer screening with low-dose computed tomography,” said study co-senior author Sam Hanash, M.D., Ph.D., professor of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center.

Released:
11-Jul-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
john_mendelsohn.jpg

Article ID: 696283

Mendelsohn shares Tang Prize for leadership in developing targeted therapy

University of Texas M. D. Anderson Cancer Center

Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to block cancer-promoting growth factor receptors on the surface of cancer cells.

Released:
18-Jun-2018 11:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
Cortes.jpg
  • Embargo expired:
    16-Jun-2018 2:30 AM EDT

Article ID: 696175

Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML

University of Texas M. D. Anderson Cancer Center

A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML) linked to a genetic mutation called FMS-like internal tandem duplications (FLT3-ITD).

Released:
15-Jun-2018 10:00 AM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
148380_Sharma_P11.jpg

Article ID: 696198

Researchers Find Combination Can Enhance Ipilimumab Immunotherapy

University of Texas M. D. Anderson Cancer Center

Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation.

Released:
15-Jun-2018 4:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
LaurenByers.jpg
  • Embargo expired:
    11-Jun-2018 4:00 PM EDT

Article ID: 695948

PARP Inhibitor Improves Overall Response Rates in Small Cell Lung Cancer Patients

University of Texas M. D. Anderson Cancer Center

In a randomized, Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients – those whose tumors expressed SLFN11— who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the PARP-inhibitor sensitivity in SCLC.

Released:
11-Jun-2018 3:20 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment
Marszalek.jpg
  • Embargo expired:
    11-Jun-2018 11:00 AM EDT

Article ID: 695886

MD Anderson Therapeutics Discovery team identifies and advances a drug that targets metabolic vulnerability and impairs cancer cell growth and survival

University of Texas M. D. Anderson Cancer Center

A drug discovered and advanced by The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) and the Center for Co-Clinical Trials (CCCT) inhibits a vital metabolic process required for cancer cells’ growth and survival.

Released:
8-Jun-2018 6:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Comment

Showing results

110 of 1188





Chat now!